PEG300 (Polyethylene glycol 300) is a polymer formed from repeating units of ethylene glycol that is water soluble, low immunogenicity, and biocompatible. PEG300 is a neutral polymer with a molecular weight of 300.

METHODS: Human colorectal adenocarcinoma cells Caco-2 were treated with PEG300 (30 w/v% in 100 μL) for 30 min, and cell growth inhibition was detected by MTT.
RESULTS: PEG300 treatment severely reduced cell viability, and the cell survival rate was only 20%. [1]

METHODS: To study the effect of Dasatinib on diabetic cardiomyopathy, Dasatinib (5 mg/kg in 10% DMSO + 90% PEG-300) was administered by gavage to BKS.Cg-+Leprdb/+Leprdb/OlaHsd (db/db) mice once a week for four weeks.
RESULTS: Dasatinib counteracted obesity in the heart and bone marrow as well as cardiac fibrosis. [2]
METHODS: To test the in vivo effects of treatment with ALW-II-41-27 (an EPHA2 inhibitor) and/or cetuximab, cetuximab (25 mg/kg in 10% 1-methyl-2-pyrrolidinone + 90% PEG 300 twice weekly) and ALW-II-41-27 (30 mg/kg/day) were injected intraperitoneally into balb/c athymic (nu+/nu+) mice bearing human colorectal adenocarcinoma tumor HCT15 for six weeks.
RESULTS: The combination of ALW-II-41-27 and cetuximab significantly inhibited tumor growth. [3]

DMSO: 100.00 mg/mL (138.34 mM), Sonication is recommended.

H2O: 50.00 mg/mL (69.17 mM), Sonication is recommended.